Please enable Javascript
RLT
Radioligand therapy prostate-specific membrane antigen
Advertisement
PSMAfore: Radioligand Therapy in the Future of Prostate Cancer Treatment
Oliver Sartor, MD
RLT
|
November 21, 2024
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
View More
Uromigos Live 2024 Radioligands Part 5: Novel Radioligands in CRPC
Brian Rini, MD, FASCO
RLT
|
October 29, 2024
The panel discusses the emerging field of PSMA-targeted alpha radioligand therapy, with a focus on HK2.
View More
Uromigos Live 2024 Radioligands Part 4: PEACE-3 Results from ESMO 2024
Brian Rini, MD, FASCO
RLT
|
October 29, 2024
The panel discusses the results of PEACE-3, which evaluated enzalutamide with or without radium-223 for MCRPC.
View More
Uromigos Live 2024 Radioligands Part 3: UpFront PSMA Results from ESMO 2024
Brian Rini, MD, FASCO
RLT
|
October 29, 2024
The panel discusses two significant trials in metastatic hormone-sensitive prostate cancer.
View More
Uromigos Live 2024 Radioligands Part 2: SPLASH Results from ESMO 2024
Brian Rini, MD, FASCO
RLT
|
October 25, 2024
Part 2 of the Radioligands session from Uromigos Live 2024 features a discussion on the SPLASH results from ESMO 2024.
View More
Uromigos Live 2024 Radioligands Part 1: VISION and PSMAFore Discussion
Brian Rini, MD, FASCO
RLT
|
October 24, 2024
The first part of five segments from the Uromigos Live 2024 session on radioligands.
View More
Positive Phase I Data of 177Lu rhPSMA-10.1 Supports Phase II Trial for mCRPC
Emily Menendez
RLT
|
October 9, 2024
Early phase I data on 177Lu rhPSMA-10.1 has demonstrated an encouraging safety profile for the novel radioligand therapy.
Read More
Radioligands: Live Session From The Uromigos Live & Unplugged 2024
Brian Rini, MD, FASCO
RLT
|
October 3, 2024
The Radioligands panel at Uromigos Live & Unplugged 2024 explored the role of RLT in prostate cancer treatment.
View More
ESMO Congress 2024 GU Round-Up: Prostate Cancer
Christopher Wallis, MD, PhD, FRCSC
CRPC
|
October 1, 2024
Drs. Tawagi and Wallis review the PEACE-III, STAMPEDE, UpFrontPSMA, and SPLASH studies trials at the ESMO Congress 2024.
View More
SPLASH: Comparative Outcomes of PSMA Radioligand Therapy Versus ARPI Switch in mCRPC
Karine Tawagi, MD
CRPC
|
October 3, 2024
SPLASH continues to show benefit for PSMA RLT in mCRPC and adds to this consideration in the pre-chemotherapy setting.
Read More
Quantitative Analysis of 68Ga-PSMA-11 PET, Clinical Outcomes in Patients With mCRPC
Katy Marshall
RLT
|
October 17, 2024
177Lu-PSMA-617 is a PSMA-targeted radioligand therapy in patients with mCRPC.
Read More
De-escalated AcPSMA With and Without LuPSMA Offers Better Tolerability for Advanced Prostate Cancer
Emily Menendez
RLT
|
October 17, 2024
Multiple cycles of AcPSMA can cause side effects including salivary gland toxicity and xerostomia.
Read More
Efficacy and Toxicity of 177Lu-PSMA-617 for mCRPC in a Real-World Setting
Vishnu Murthy
CRPC
|
July 8, 2024
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
View More
SNMMI 2024: Dosimetry of 177Lu-PSMA RLTs, FLEX-MRT, and More
Jérémie Calais, MD, PhD
RLT
|
June 20, 2024
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
View More
Nuclear Medicine Highlights From the SNMMI 2024 Annual Meeting
Jérémie Calais, MD, PhD
RLT
|
June 20, 2024
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
View More
PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC
Oliver Sartor, MD
RLT
|
June 18, 2024
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
View More
Rationale, Dose Escalation for 67Cu-SAR-bisPSMA in Patients With mCRPC
Geoffrey Johnson, MD, PhD
RLT
|
June 17, 2024
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
View More
177Lu-PSMA-617 Boosts Antitumor Effects in Real-World Setting for mCRPC
Emily Menendez
Prostate Cancer
|
June 13, 2024
177Lu-PSMA-617 in heavily pretreated patients with late-stage mCRPC provided beneficial antitumor effects.
Read More
Intensified RLT Boosts Treatment Efficacy in Patients With mCRPC
Emily Menendez
CRPC
|
June 13, 2024
Intensified RLT with escalation of the first 3 cycles to 10-11 GBq for high-volume mCRPC may increase treatment efficacy.
Read More
PSMAfore: Informing Future Trials of 177Lu-PSMA-617 Versus Chemotherapy for mCRPC
Karine Tawagi, MD
Advancements in Oncology
|
June 12, 2024
Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results.
View More
Load More
Advertisement
Advertisement
Advertisement